142 related articles for article (PubMed ID: 11685102)
1. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399.
Khanna A
Transplantation; 2001 Oct; 72(8):1352-3. PubMed ID: 11685102
[No Abstract] [Full Text] [Related]
2. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.
Haque T; Taylor C; Wilkie GM; Murad P; Amlot PL; Beath S; McKiernan PJ; Crawford DH
Transplantation; 2001 Oct; 72(8):1399-402. PubMed ID: 11685111
[TBL] [Abstract][Full Text] [Related]
3. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.
Aspord C; Laurin D; Richard MJ; Vie H; Chaperot L; Plumas J
Am J Transplant; 2011 Dec; 11(12):2613-26. PubMed ID: 21883919
[TBL] [Abstract][Full Text] [Related]
4. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.
O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
Springer Semin Immunopathol; 1998; 20(3-4):455-91. PubMed ID: 9870257
[No Abstract] [Full Text] [Related]
6. Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up.
Haque T; McAulay KA; Kelly D; Crawford DH
Transplantation; 2010 Jul; 90(1):93-4. PubMed ID: 20606564
[No Abstract] [Full Text] [Related]
7. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
8. Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
Dierickx D; Tousseyn T; De Wolf-Peeters C; Pirenne J; Verhoef G
Leuk Lymphoma; 2011 Jun; 52(6):950-61. PubMed ID: 21338285
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
[TBL] [Abstract][Full Text] [Related]
11. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.
Haque T; Crawford DH
Springer Semin Immunopathol; 1998; 20(3-4):375-87. PubMed ID: 9870252
[No Abstract] [Full Text] [Related]
12. Cytotoxic T cells and immunotherapy.
Kitchingman GR; Rooney C
Pediatr Radiol; 1998 Jul; 28(7):489-91. PubMed ID: 9662564
[TBL] [Abstract][Full Text] [Related]
13. An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy.
Elliott J; Avdic S; Selim AG; Clancy L; Atkins E; Blyth E; Ritchie D; Gottlieb D; Bajel A
Br J Haematol; 2021 Oct; 195(1):140-143. PubMed ID: 34180535
[No Abstract] [Full Text] [Related]
14. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines.
Rooney CM; Aguilar LK; Huls MH; Brenner MK; Heslop HE
Curr Top Microbiol Immunol; 2001; 258():221-9. PubMed ID: 11443864
[No Abstract] [Full Text] [Related]
15. Immunotherapy for Epstein-Barr virus-associated malignancies.
Long HM; Parsonage G; Fox CP; Lee SP
Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
[TBL] [Abstract][Full Text] [Related]
16. [Adoptive immune therapy using EBV-specific CTL].
Kuzushima K; Morishima T
Nihon Rinsho; 1997 Feb; 55(2):473-8. PubMed ID: 9046843
[TBL] [Abstract][Full Text] [Related]
17. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
[TBL] [Abstract][Full Text] [Related]
18. When magic bullets miss their mark.
Levitsky HI
Blood; 2001 Feb; 97(4):833. PubMed ID: 11159502
[No Abstract] [Full Text] [Related]
19. Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.
Rowe M; Niedobitek G; Young LS
Springer Semin Immunopathol; 1998; 20(3-4):389-403. PubMed ID: 9870253
[No Abstract] [Full Text] [Related]
20. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.
Gandhi MK; Wilkie GM; Dua U; Mollee PN; Grimmett K; Williams T; Whitaker N; Gill D; Crawford DH
Am J Transplant; 2007 May; 7(5):1293-9. PubMed ID: 17425621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
